An announcement from EyePoint Pharmaceuticals (EYPT) is now available.
EyePoint Pharmaceuticals, Inc. stockholders convened via webcast for the 2024 Annual Meeting, where they approved significant amendments to the company’s long-term incentive and stock purchase plans. These amendments included a substantial increase in the authorized shares for issuance, raising the non-employee director compensation, and adjusting the incentive stock option limit. Additionally, the election of directors and other proposals, such as executive officer compensation and the ratification of the company’s independent auditor, received stockholder approval, with Deloitte & Touche LLP set to continue as the auditor for the next fiscal year.
See more data about EYPT stock on TipRanks’ Stock Analysis page.
